Product Images Cleviprex

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 12 images provide visual information about the product associated with Cleviprex NDC 10122-610 by Chiesi Usa, Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Clevidipine Structure and Formula - cleviprex 1

Clevidipine Structure and Formula - cleviprex 1

Package Label - Principal Display Panel - 50mg/100mL Vial Label - cleviprex 10

Package Label - Principal Display Panel - 50mg/100mL Vial Label - cleviprex 10

This is a set of instructions for storing and administering medication via a vial stored in a carton. The vial should be kept refrigerated at 2-6°C (36-46°F) and protected from light. If transported at room temperature (25°C or 77°F) it should be used within 2 months of the expiration date on the carton. The label number is CTCP-028-0322-01. Before use, gently invert the vial. No further information is available.*

Package Label - Principal Display Panel - 50mg/100mL Inner Carton - cleviprex 11

Package Label - Principal Display Panel - 50mg/100mL Inner Carton - cleviprex 11

The text describes Clevidipine, an injectable emulsion containing 50 mg/ml of clevidipine. It is stored under refrigerated conditions and can be stored for up to 2 months at room temperature in its carton. The emulsion is packaged in single-use vials that should be used promptly after opening or within 12 hours. It contains EDTA, which inhibits microbial growth up to 12 hours, but contamination can cause life-threatening illness. The product is manufactured by Fresenius Kabi in Austria and contraindicated for patients with allergies to soy or eggs, bile duct obstruction, or severe aortic stenosis. The dosage should be determined by the accompanying package insert, and unused portions should be discarded.*

Package Label - Principal Display Panel - 50mg/100mL Outer Carton - cleviprex 12

Package Label - Principal Display Panel - 50mg/100mL Outer Carton - cleviprex 12

This appears to be a label for Cleviprex, an injectable emulsion used for blood pressure control. The label provides the strength and quantity of medication per mL, as well as the National Drug Code (NDC) and storage directions.*

Figure 1. Mean change in systolic blood pressure (mmHg) during 30-minute infusion, ESCAPE-1 (preoperative) - cleviprex 2

Figure 1. Mean change in systolic blood pressure (mmHg) during 30-minute infusion, ESCAPE-1 (preoperative) - cleviprex 2

This is a graph showing the mean change from baseline in systolic blood pressure (measured in mmHg) over time (in minutes) for a drug called Clevidipine and a placebo. There are no additional details available.*

Figure 2. Mean change in systolic blood pressure (mmHg) during 30-minute infusion, ESCAPE-2 (postoperative) - cleviprex 3

Figure 2. Mean change in systolic blood pressure (mmHg) during 30-minute infusion, ESCAPE-2 (postoperative) - cleviprex 3

The text describes a chart or graph showing the mean change from baseline systolic blood pressure measured in mmHg over a 30-minute infusion. The chart appears to show some participants leaving early and only providing data at certain time intervals. The time intervals provided are at 10, 15, 20, 25, and 30 minutes.*

Figure 3. Mean change in heart rate (bpm) during 30-minute infusion, ESCAPE-1 (preoperative) - cleviprex 4

Figure 3. Mean change in heart rate (bpm) during 30-minute infusion, ESCAPE-1 (preoperative) - cleviprex 4

Figure 4. Mean change in heart rate (bpm) during 30-minute infusion, ESCAPE-2 (postoperative) - cleviprex 5

Figure 4. Mean change in heart rate (bpm) during 30-minute infusion, ESCAPE-2 (postoperative) - cleviprex 5

Figure 5. Mean percent change in SBP (%) during the first 30 minutes of infusion, VELOCITY (severe hypertension) - cleviprex 6

Figure 5. Mean percent change in SBP (%) during the first 30 minutes of infusion, VELOCITY (severe hypertension) - cleviprex 6

Package Label - Principal Display Panel - 25mg/50mL Vial Label - cleviprex 7

Package Label - Principal Display Panel - 25mg/50mL Vial Label - cleviprex 7

Package Label - Principal Display Panel - 25mg/50mL Inner Carton - cleviprex 8

Package Label - Principal Display Panel - 25mg/50mL Inner Carton - cleviprex 8

This is a description of a medication containing 25 milligrams of a substance called Contont in a 50 milliliter solution with a concentration of 0.5 milligrams per milliliter. The medication is stored in a vial and should be kept at room temperature. The NDC number is 1012261001. Dosage information is provided in the package insert, and the medication should not be used after the expiration date indicated on the carton or vial, or 2 months after the date indicated on the carton. The medication should not be used in patients with allergies and should not be refrigerated or frozen. Additional administration precautions are also provided.*

Package Label - Principal Display Panel - 25mg/50mL Outer Carton - cleviprex 9

Package Label - Principal Display Panel - 25mg/50mL Outer Carton - cleviprex 9

This is a label of a medicine, containing euidipina, with a concentration of 25mg/50mL (0.5mg/mL). It comes in a carton of ten single-use vials and is for intravenous use only. The rest of the text is not readable.*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.